

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. -8. (canceled).

9. (currently amended): A method for measuring an occupying ratio of a compound

1. bound to an epitope region recognized by antibodies 45531.111 and 45523.111 of strong binding site of CCR5 on a CCR5 expressing cell or a membrane fraction thereof, which comprises and

2. having a ligand binding inhibitory effect after 6 to 10 washings, said method comprising:

- (a) allowing a CCR5 expressing cell or a membrane fraction thereof to contact with a compound to be tested,
- (b) allowing the test compound-bound cell or a membrane fraction thereof prepared in the above step (a) to contact with a labeled anti-CCR545531.111 or 45523.111 antibody, wherein when an antagonist or an agonist is bound to the strong binding site of CCR5, the antibody has a property of not binding to CCR5, or an isotype control of the labeled anti-CCR5 antibody or a labeled isotype control of the 45531.111 or 45523.111 antibody, and
- (c) calculating an occupying ratio of the compound bound to the epitope region recognized by the antibodies 45531.111 and 45523.111 strong binding site of CCR5 on the cell or membrane fraction thereof, based on the ratio of:

a bound amount of ~~the anti-CCR545531.111 or 45523.111 antibody~~ when the compound is bound to CCR5 corrected by using the labeled isotype control to a bound amount of ~~the anti-CCR545531.111 or 45523.111 antibody~~ when the compound is not bound to CCR5 corrected by using the labeled isotype control, which is defined as 100%.

10.-33. (canceled).

34. (new): The method according to claim 9, wherein the compound has an IC₅₀ values of 1.5 nmol/l to 4.2 nmol/l for the ligand binding inhibitory activity after being subjected to 8 washings.

35. (new): The method according to claim 9, wherein the compound has a strong ligand binding inhibitory effect after being subjected to 8 washings.